Loading...
Loading...
Rosetta
Genomics Ltd.
ROSG, a leading developer and provider of
microRNA-based molecular diagnostics, today announced that the Company has
received two notices of allowance from the U.S. Patent and Trademark Office
("USPTO") for Patent Applications 12/661,041 and 12/850,091.
The allowed claims of 12/661,041, entitled "microRNAs and Uses Thereof," cover
the composition of matter for miR-29c*, as well as sequence variants (90%
identical thereto), a vector and a probe comprising the same. miR-29c* is a
core element in the Company's lead commercial product, miRview^® mets^2
diagnostic assay for the identification of the tumor of origin in Cancer of
Unknown and Uncertain Primary ("CUP").
The allowed claims of 12/850,091, entitled "Viral and Viral Associated MiRNAs
and Uses Thereof," cover the composition of matter for herpes simplex virus 1
miR-H3, miR-H4 and miR-H5, as well as sequence variants (80% identical
thereto), a vector and a complementary sequence comprising the same.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in